Why Arrowhead Pharmaceuticals Shares Soared More Than 23% Today
This marks a historic day since the company’s first FDA approval.
biotech stocks arrowhead pharmaceutical (hero +23.25%) I experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company’s stock rose more than 23% on the back of its latest earnings release.
flying arrow
At the market close the day before, Arrowhead finalized its full fiscal 2025 results. The company’s revenue in the period exceeded $829 million, primarily due to inflows of licensing and collaboration funds, which is significantly higher than the $3.6 million reported in 2024.
Image source: Getty Images.
Additionally, net loss narrowed to $1.6 million, compared to a loss of $599 million the previous year.
But Arrowhead’s most important event isn’t its annual earnings release. Earlier this month, the U.S. Food and Drug Administration (FDA) approved Redemplo for the treatment of adults with familial chylomicronemia syndrome (FCS). This is a rare genetic disorder that impairs the body’s ability to metabolize fat. Redemplo is Arrowhead’s first FDA approval.
arrowhead pharmaceutical
today’s change
(23.25%) $10.88
current price
$57.67
Key data points
market capitalization
6 billion dollars
work range
$45.67 -$59.13
52 week range
$9.57 -$59.13
volume
281K
average volume
2.3 million
gross profit
96.06%
dividend yield
Not applicable
I’m planning to go to a pharmacy near me soon.
This is an exciting and memorable time for Arrowhead as it looks to add new revenue streams through Redemplo. Meanwhile, funding is also being raised through very important collaborations and must continue to be done as we prepare to commercialize new drugs. This is a company on the move, so it’s a stock investors should keep an eye on, especially biotech enthusiasts.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
